Study on the Safety and Tolerance of Mesenchymal Stem Cells Mediated by Arthroscopy in Patients With Osteoarthritis - Trial NCT06082440
Access comprehensive clinical trial information for NCT06082440 through Pure Global AI's free database. This Phase 1 trial is sponsored by First Affiliated Hospital of Wannan Medical College and is currently Not yet recruiting. The study focuses on Osteoarthritis, Knee. Target enrollment is 18 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
First Affiliated Hospital of Wannan Medical College
Timeline & Enrollment
Phase 1
Oct 10, 2023
Jan 10, 2026
Primary Outcome
Within 4 weeks after treatment, evaluate the incidence and severity of adverse events.,Within 4 weeks after treatment, evaluate the Maximum Tolerable Dose (MTD).
Summary
The goal of this clinical trial is to evaluate the safety and tolerability of human umbilical
 cord mesenchymal stem cells mediated by arthroscopy in patients with knee osteoarthritis.
 This experiment proposes to enroll 18-22 patients. The experimental drug is human umbilical
 cord mesenchymal stem cells.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06082440
Non-Device Trial